Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NBI-827104 · ACT-709478

Small molecule · Antagonist of T-type calcium channel · developed by NEUROCRINE BIOSCIENCES

Phase 2 Most advanced trial (none active)
NBIX Developer
1 Registered trials

What is NBI-827104?

NBI-827104 is a T-type calcium channel blocker studied in epileptic encephalopathy and continuous spike and wave during sleep.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ACT-709478
Drug type
Small molecule
Targets
T-type calcium channel
Mechanism
Antagonist of T-type calcium channel
Therapy area
Neurology
Developer
NEUROCRINE BIOSCIENCES (NBIX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
3Z7U1U8Z9E

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05301894 Phase 2 Epileptic Encephalopathy Terminated NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Continuous Spike and Wave During SleepEpileptic Encephalopathy

More from NEUROCRINE BIOSCIENCES

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NBIX page.

Follow NBIX, the company behind NBI-827104

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.